102 Participants Needed

Acuity Software for Autism Spectrum Disorder

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Experiad LLC
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify whether participants must stop taking their current medications.

Is Acuity Software for Autism Spectrum Disorder safe for humans?

The research articles provided do not contain specific safety data for Acuity Software for Autism Spectrum Disorder.12345

How does the Acuity treatment for Autism Spectrum Disorder differ from other treatments?

The Acuity treatment for Autism Spectrum Disorder is unique because it likely involves software or technology-based methods, which may include machine learning or mobile health technology, to aid in early detection and assessment of autism. This approach contrasts with traditional methods that rely heavily on behavioral observation and clinical expertise, potentially offering a more accessible and efficient way to identify autism risk in diverse settings.678910

What is the purpose of this trial?

This study will test feature enhancements to a behavioral therapy data collection software (Motivity) that will add a new clinical decision support module, called Acuity. Acuity is a Quality Improvement (QI) intervention targeted at Behavior Analysts (BAs) and Behavior Technicians (BTs) that aims to improve the delivery of autism behavioral therapy. Subjects will be staff recruited from existing Motivity customers.

Eligibility Criteria

This trial is for Behavior Analysts (BAs) and Behavior Technicians (BTs) who use the Motivity software in their practice. It's aimed at those working with individuals with Autism Spectrum Disorder to improve behavioral therapy delivery.

Inclusion Criteria

Behavior Analysts and Behavior Technicians treating kids with autism
Must be employed by one of the autism treatment clinics that have agreed to participate in the study
Must be employed by Experiad customers who are using Motivity software as part of their practice

Exclusion Criteria

My condition does not match any specific criteria listed.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Implementation

Implementation of Acuity software enhancements for behavioral therapy data collection and clinical decision support

18 months

Follow-up

Participants are monitored for the effectiveness and adoption of Acuity software enhancements

4-8 weeks

Treatment Details

Interventions

  • Acuity
Trial Overview The study is evaluating Acuity, a new clinical decision support module within the Motivity software. This Quality Improvement intervention is designed to enhance how BAs and BTs collect data and make decisions during autism behavioral therapy.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Acuity-EnhancedExperimental Treatment1 Intervention
Group II: Acuity-BasicExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Experiad LLC

Lead Sponsor

Trials
3
Recruited
130+

Findings from Research

The automated trigger algorithm successfully identified potential adverse events in 8% of parent-reported ADHD assessments, leading to timely clinician reviews and changes in care plans for 46% of actionable alerts.
Patients with triggered alerts showed significantly worsened ADHD severity scores prior to the alerts, indicating that the algorithm effectively highlighted those needing immediate attention and intervention.
Timely Interventions for Children with ADHD through Web-Based Monitoring Algorithms.Oppenheimer, J., Ojo, O., Antonetty, A., et al.[2020]
The comprehensive body system review (BSR) in the Safety Monitoring Uniform Report Form (SMURF) identified 129 additional adverse events (AEs) in pediatric patients, significantly more than the 48 AEs from the general inquiry and 16 from the drug-specific inquiry, highlighting its effectiveness in capturing important safety data.
Parents found the detailed BSR acceptable and satisfactory, while clinicians did not share the same level of acceptance, indicating a potential gap in the perceived utility of detailed adverse event reporting methods in pediatric psychopharmacology.
Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology.Greenhill, LL., Vitiello, B., Fisher, P., et al.[2007]
A study involving 71 adults with autism spectrum disorder (ASD) found that genotyping the CYP2D6 enzyme can help predict drug tolerability and prevent adverse reactions to medications like risperidone and aripiprazole.
Participants with the intermediate (IM) CYP2D6 phenotype experienced the highest rates of neurological and psychiatric adverse events, especially when taking multiple medications, highlighting the importance of personalized medicine in managing ASD treatment.
CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysis.Ballester, P., Espadas, C., Almenara, S., et al.[2023]

References

Timely Interventions for Children with ADHD through Web-Based Monitoring Algorithms. [2020]
Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. [2007]
Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey. [2020]
CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysis. [2023]
National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment. [2018]
Searching for a minimal set of behaviors for autism detection through feature selection-based machine learning. [2018]
Autism detection in early childhood (ADEC): reliability and validity data for a Level 2 screening tool for autistic disorder. [2014]
Diagnosing Autism Spectrum Disorder Without Expertise: A Pilot Study of 5- to 17-Year-Old Individuals Using Gazefinder. [2021]
Use of machine learning to shorten observation-based screening and diagnosis of autism. [2021]
Using mobile health technology to assess childhood autism in low-resource community settings in India: An innovation to address the detection gap. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security